Cheng Zou

Cheng Zou


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
YMYang Mei
Yang Mei
KRKehan Ren
Kehan Ren
YLYijie Liu
Yijie Liu
AMAnnabel Ma
Annabel Ma
ZXZongjun Xia
Zongjun Xia
PJPeng Ji
Peng Ji
Myelodysplastic syndromes (MDS) are age-related myeloid neoplasms with increased risk of progression to acute myeloid leukemia (AML). The mechanisms of transformation of MDS to AML are poorly understood, especially in relation to the aging microenvironment. We previously established an mDia1/miR-146a double knockout (DKO) mouse model phenocopying MDS. These mice develop age-related pancytopenia with oversecretion of proinflammatory cytokines. Here, we found that most of the DKO mice underwent leukemic transformation at 12–14 months of age. These mice showed myeloblast replacement of fibrotic bone marrow and widespread leukemic infiltration. Strikingly, depletion of IL-6 in these mice largely rescued the leukemic transformation and markedly extended survival. Single-cell RNA sequencing analyses revealed that DKO leukemic mice had increased monocytic blasts that were reduced with IL-6 knockout. We further revealed that the levels of surface and soluble IL-6 receptor (IL-6R) in the bone marrow were significantly increased in high-risk MDS patients. Similarly, IL-6R was also highly expressed in older DKO mice. Blocking of IL-6 signaling significantly ameliorated AML progression in the DKO model and clonogenicity of CD34-positive cells from MDS patients. Our study establishes a mouse model of progression of age-related MDS to AML and indicates the clinical significance of targeting IL-6 signaling in treating high-risk MDS.

5 April 2024 in Science Advances
Verified
Journal Article
Open access
CZCheng Zou
Cheng Zou
WLWenchao Li
Wenchao Li
YZYuanzhen Zhang
Yuanzhen Zhang
NFNinghan Feng
Ninghan Feng
SCSaisai Chen
Saisai Chen
DZDingxiao Zhang
Dingxiao Zhang
Histopathological heterogeneity is a hallmark of prostate cancer (PCa). Using spatial and parallel single-nucleus transcriptomics, we report an androgen receptor (AR)–positive but neuroendocrine-null primary PCa subtype with morphologic and molecular characteristics of small cell carcinoma. Such small cell–like PCa (SCLPC) is clinically aggressive with low AR, but high stemness and proliferation, activity. Molecular characterization prioritizes protein translation, represented by up-regulation of many ribosomal protein genes, and SP1, a transcriptional factor that drives SCLPC phenotype and overexpresses in castration-resistant PCa (CRPC), as two potential therapeutic targets in AR-indifferent CRPC. An SP1-specific inhibitor, plicamycin, effectively suppresses CRPC growth in vivo. Homoharringtonine, a Food And Drug Administration–approved translation elongation inhibitor, impedes CRPC progression in preclinical models and patients with CRPC. We construct an SCLPC-specific signature capable of stratifying patients for drug selectivity. Our studies reveal the existence of SCLPC in admixed PCa pathology, which may mediate tumor relapse, and establish SP1 and translation elongation as actionable therapeutic targets for CRPC.

31 August 2024 in Cancer Letters
Verified
Journal Article
Closed access
QHQinju He
Qinju He
YZYuanzhen Zhang
Yuanzhen Zhang
WLWenchao Li
Wenchao Li
SCSaisai Chen
Saisai Chen
JXJiangling Xiong
Jiangling Xiong
DZDingxiao Zhang
Dingxiao Zhang

2 April 2024 in Oncogene
Verified
Journal Article
Closed access
PDF file
MCMengjie Chen
Mengjie Chen
CZCheng Zou
Cheng Zou
YTYu Tian
Yu Tian
WLWenchao Li
Wenchao Li
YLYingying Li
Yingying Li
DZDingxiao Zhang
Dingxiao Zhang

9 May 2024 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
PDF file
CZCheng Zou
Cheng Zou
JZJinwei Zhu
Jinwei Zhu
JXJiangling Xiong
Jiangling Xiong
YTYu Tian
Yu Tian
YPyousong peng
yousong peng
DZDingxiao Zhang
Dingxiao Zhang
Integrin genes are widely involved in tumorigenesis. Yet, a comprehensive characterization of integrin family members and their interactome at the pan-cancer level is lacking. Here, we systematically analyzed integrin family in approximately 10,000 tumors across 32 cancer types. Globally, integrins represent a frequently altered and misexpressed pathway, with alteration and dysregulation overall being protumorigenic. Expression dysregulation, better than mutational landscape, of integrin family successfully identifies a subgroup of aggressive tumors with a high level of proliferation and stemness. The results reveal that several molecular mechanisms collectively regulate integrin expression in a context-dependent manner. For potential clinical usage, we constructed a weighted scoring system, integrinScore, to measure integrin signaling patterns in individual tumors. Remarkably, integrinScore was consistently correlated with predefined molecular subtypes in multiple cancers, with integrinScore-high tumors being more aggressive. Importantly, integrinScore was cancer-dependent and closely associated with proliferation, stemness, tumor microenvironment, metastasis, and immune signatures. IntegrinScore also predicted patients’ response to immunotherapy. By mining drug databases, we unraveled an array of compounds that may modulate integrin signaling. Finally, we built a user-friendly database, Pan-cancer Integrin Explorer (PIExplorer; http://computationalbiology.cn/PIExplorer), to facilitate researchers to explore integrin-related knowledge. Collectively, we provide a comprehensive characterization of integrins across cancers and offer gene-specific and cancer-specific rationales for developing integrin-targeted therapy.

18 June 2020 in Molecular & Cellular Oncology
Verified
Journal Article
Closed access
CZCheng Zou
Cheng Zou
DZDingxiao Zhang
Dingxiao Zhang
Alternative splicing (AS) analysis across the entire spectrum of human prostate cancer evolution reveals the unexpected findings that intron retention is a hallmark of stemness and tumor aggressiveness, and androgen receptor controls a splicing program distinct from its transcriptional regulation. Importantly, twisted activity of the spliceosome causing abnormal AS landscape represents a therapeutic vulnerability in aggressive prostate cancer.